400
These two DOACs were compared in the first head-to-head trial to compare risks of thromboembolic stroke, intracranial hemorrhage (ICH), major extracranial bleeding including major gastrointestinal bleeding, and mortality in patients with
nonvalvular AF.
What is rivaroxaban (Xarelto) and dabigatran (Pradaxa)